[1] [1] A. W€ohrer, T. Waldh€or, H. Heinzl, M. Hackl, J. Feichtinger, U. Gruber-M€osenbacher, A. Kiefer, H. Maier, R. Motz, A. Reiner-Concin, B. Richling, C. Idriceanu, M. Scarpatetti, R. Sedivy, H. C. Bankl, W. Stiglbauer, M. Preusser, K. R€ossler, J. A. Hainfellner, “The Austrian Brain Tumour Registry: A cooperative way to establish a population-based brain tumour registry," J.Neurooncol. 95, 401–411 (2009).

[2] [2] I. Jovcevska, N. Kocevar, R. Komel, “Glioma and glioblastoma – how much do we (not) know?" Mol. Clin. Oncol. 1, 935–941 (2013).

[3] [3] R. Li, X. Chen, Y. You, X. Wang, Y. Liu, Q. Hu,W. Yan, “Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics," Oncotarget, 6, 30968–30974 (2015).

[4] [4] S. Watkins, S. Robel, I. F. Kimbrough, S. M. Robert, G. Ellis-Davies, H. Sontheimer, “Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells," Nat. Commun. 5, 4196 (2014).

[5] [5] H. F. Dvorak, “Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma," Am. J. Pathol. 162, 1747–1757 (2003).

[6] [6] S. W. Cole, A. S. Nagaraja, S. K. Lutgendorf, P. A. Green, A. K. Sood, “Sympathetic nervous system regulation of the tumour microenvironment," Nat. Rev. Cancer. 15, 563–572 (2015).

[7] [7] G. N. Armaiz-Pena, S. W. Cole, S. K. Lutgendorf, A. K. Sood, “Neuroendocrine influences on cancer progression," Brain Behav. Immun. 30, S19–S25 (2013).

[8] [8] G. Qiao, M. Chen, M. J. Bucsek, E. A. Repasky, B. L. Hylander, “Adrenergic signaling: A targetable checkpoint limiting development of the antitumor immune response," Front. Immunol. 9, 164 (2018).

[9] [9] B. B. Eldeeb, E. M. Hammond, D. J. Worthington, J. R. Mann, “Urinary catecholamines and their metabolites in management of neuroblastoma," Pediatr. Hematol. Oncol. 5, 229–237 (1988).

[10] [10] T. I. Barron, R. M. Connolly, L. Sharp, K. Bennett, K. Visvanathan, “Beta blockers and breast cancer mortality: A population-based study," J. Clin. Oncol. 29, 2635–2644 (2011).

[11] [11] A. Melhem-Bertrandt, M. Chavez-Macgregor, X. Lei, E. N. Brown, R. T. Lee, F. Meric-Bernstam, A. K. Sood, S. D. Conzen, G. N. Hortobagyi, A. M. Gonzalez-Angulo, “Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer," J. Clin. Oncol. 29, 2645–2652 (2011).

[12] [12] E. S. Diaz, B. Y. Karlan, A. J. Li, “Impact of beta blockers on epithelial ovarian cancer survival," Gynecol Oncol. 127, 375–378 (2012).

[13] [13] V. De Giorgi, M. Grazzini, S. Gandini, S. Benemei, T. Lotti, N. Marchionni, P. Geppetti, “Treatment with β-blockers and reduced disease progression in patients with thick melanoma," Arch. Int. Med. 171, 779–781 (2011).

[14] [14] K. V. Quoc Lu'o'ng, L. T. Nguyên, “The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms," Cancer Manag. Res. 4, 431–445 (2012).

[15] [15] Q. Song, Q. Ji, Q. Li, “The role and mechanism of β-arrestins in cancer invasion and metastasis (Review)," Int. J. Mol. Med. 41, 631–639 (2018).

[16] [16] C. A. Izeboud, J. A. Mocking, M. Monshouwer, A. S. van Miert, R. F. Witkamp, “Participation of betaadrenergic receptors on macrophages in modulation of LPS-induced cytokine release," J. Recept. Signal Transduct. Res. 19, 191–202 (1999).

[17] [17] J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis," Nat. Rev. Cancer. 4, 71–78 (2004).

[18] [18] A. Mantovani, P. Allavena, A. Sica, F. Balkwill, “Cancer-related inflammation," Nature 454, 436–444 (2008).

[19] [19] S. Yousif, C. Marie-Claire, F. Roux, J. M. Scherrmann, X. Declèves, “Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy," Brain Res. 1134, 1–11 (2007).

[20] [20] U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature 227, 680–685 (1970).

[21] [21] H. L. Wang, T. W. Lai, “Optimization of Evans blue quantitation in limited rat tissue samples," Sci. Rep. 4, 6588 (2014).

[22] [22] A. Hoffmann, J. Bredno, M. Wendland, N. Derugin, P. Ohara, M. Wintermark, “High and low molecular weight fluorescein isothiocyanate (FITC)-dextrans to assess blood-brain barrier disruption: Technical considerations," Transl. Stroke Res. 2, 106–111 (2011).

[23] [23] D. G. Bernabe, A. C. Tamae, E. R. Biasoli, S. H. Oliveira, “Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells," Brain Behav. Immun. 25, 574–583 (2011).

[24] [24] X. Liu, W. K. Wu, L. Yu, J. J. Sung, G. Srivastava, S. T. Zhang, C. H. Cho, “Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway," J. Cell. Biochem. 105, 53–60 (2008).

[25] [25] X. Y. Huang, H. C. Wang, Z. Yuan, J. Huang, Q. Zheng, “Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via β-adrenergic receptor-dependent activation of P38/MAPK pathway," Hepatogastroenterology, 59, 889–893 (2012).

[26] [26] C. Perez Pinero, A. Bruzzone, M. G. Sarappa, L. F. Castillo, I. A. Lüthy, “Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation," Br. J. Pharmacol. 166, 721–736 (2012).

[27] [27] F. Hajighasemi, A. Mirshafiey, “In vitro sensitivity of leukemia cells to propranolol," J. Clin. Med. Res. 1, 144–149 (2009).

[28] [28] D. Zhang, Q. Y. Ma, H. T. Hu, M. Zhang, “β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkB and AP-1," Cancer Biol. Ther. 10, 19–29 (2010).

[29] [29] X. Liao, X. Che, W. Zhao, D. Zhang, T. Bi, G. Wang, “The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kB signaling," Oncol. Rep. 24, 1669–1676 (2010).

[30] [30] D. G. Powe, M. J. Voss, K. S. Zanker, H. O. Habashy, A. R. Green, I. O. Ellis, F. Entschladen, “Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival," Oncotarget, 1, 628–638 (2010).

[31] [31] N. E. Wolter, J. K. Wolter, D. J. Enepekides, M. S. Irwin, “Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma," J. Otolaryngol. Head Neck. Surg. 41, 334–344 (2012).

[32] [32] I. Sardi, L. Giunti, C. Bresci, A. M. Buccoliero, D. Degl'innocenti, S. Cardellicchio, G. Baroni, F. Castiglione, M. D. Ros, P. Fiorini, S. Giglio, L. Genitori, M. Aricò, L. Filippi, “Expression of β-adrenergic receptors in pediatric malignant brain tumors," Oncol. Lett. 5, 221–225 (2013).

[33] [33] M. R. Hara, J. J. Kovacs, E. J. Whalen, S. Rajagopal, R. T. Strachan, W. Grant, A. J. Towers, B. Williams, C. M. Lam, K. Xiao, S. K. Shenoy, S. G. Gregory, S. Ahn, D. R. Duckett, R. J. Lefkowitz, “A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1," Nature, 477(7364), 349–353 (2011).

[34] [34] J. K. Wolter, N. E. Wolter, A. Blanch, T. Partridge, L. Cheng, D. A. Morgenstern, M. Podkowa, D. R. Kaplan, M. S. Irwin, “Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma," Oncotarget, 5, 161–172 (2014).

[35] [35] A. Farin, S. O. Suzuki, M. Weiker, J. E. Goldman, J. N. Bruce, P. Canoll, “Transplanted glioma cells migrate and proliferate on host brain vasculature: A dynamic analysis," Glia. 53, 799–808 (2006).

[36] [36] D. Zagzag, R. Amirnovin, M. A. Greco, H. Yee, J. Holash, S. J. Wiegand, S. Zabski, G. D. Yancopoulos, M. Grumet, “Vascular apoptosis and involution in gliomas precede neovascularization: A novel concept for glioma growth and angiogenesis," Lab. Invest. 80, 837–849 (2000).

[37] [37] N. Nagano, H. Sasaki, M. Aoyagi, K. Hirakawa, “Invasion of experimental rat brain tumor: Early morphological changes following microinjection of C6 glioma cells," Act. Neuropathol. 86(2), 117–125 (1993).

[38] [38] L. G. Dubois, L. Campanati, C. Righy, I. D'Andrea-Meira, T. C. Spohr, I. Porto-Carreiro, C. M. Pereira, J. Balca-Silva, S. A. Kahn, M. F. DosSantos, A. Oliveira Mde, A. Ximenes-da-Silva, M. C. Lopes, E. Faveret, E. L. Gasparetto, V. Moura-Neto, “Gliomas and the vascular fragility of the blood brain barrier," Front. Cell. Neurosci. 8, 418 (2014).

[39] [39] G. Liu, J. Shi, L. Yang, L. Cao, S. M. Park, J. Cui, S. O. Marx, “Assembly of a Ca2t-dependent BK channel signaling complex by binding to β2 adrenergic receptor," EMBO J. 23, 2196–2205 (2004).

[40] [40] M. Matsushita, Y. Tanaka, K. Koike, “Studies on the mechanisms underlying beta-adrenoceptor-mediated relaxation of rat abdominal aorta," J. Smooth Muscle Res. 42, 217–225 (2006).

[41] [41] Y. Song, J. M. Simard, “beta-Adrenoceptor stimulation activates large-conductance Ca2t-activated Kt channels in smooth muscle cells frombasilar artery of guinea pig," Pflugers Arch. 430, 984–993 (1995).